Market Closed -
Nasdaq
04:00:00 2024-05-16 pm EDT
5-day change
1st Jan Change
1.68
USD
-2.33%
-8.20%
-56.36%
Synlogic : A Novel Human IL-22-Secreting Synthetic Biotic Medicine for the Treatment of Inflammatory Bowel Disease, Digestive Disease Week (DDW)
A Novel Human IL-22-
Secreting Synthetic Biotic
Medicine for the Treatment of
Inflammatory Bowel Disease
Anna Sokolovska, Ning Li, Starsha Kolodziej, JR Gao, Christopher
Bergeron, Jillian Means, Caroline Kurtz, David Hava and Mylene
Perreault.
Digestive Disease Week (DDW)
May 23, 2021
© 2021 SYNLOGIC. ALL RIGHTS RESERVED.
Disclosures
All authors were Synlogic employees and shareholders at the time the work was
performed.
© 2021 SYNLOGIC. ALL RIGHTS RESERVED.
Intestinal Homeostasis is Disrupted in IBD
Disease pathophysiology in IBD linked to compromised barrier function and increased inflammation
Mucosal healing is the next therapeutic goal to achieve stable remission in IBD patients
Zhang 2017, Neurath 2014, Bourma and Strober 2003
© 2021 SYNLOGIC. ALL RIGHTS RESERVED.
Adapted from Keir et al., 2020
IL-22 as a Therapeutic Effector
Promotes barrier function and mucosal healing
IL-22 promotes epithelial barrier functions and mucosal healing.
Extensive pre-clinical evidence supports a critical role for IL-22 in IBD.
Many IL-22 associated molecules are encoded by IBD susceptibility genes and patients with ulcerative colitis have evidence of IL-22 dysfunction.
Systemically administered hIL-22-Fc results in pharmacodynamic responses but is associated with dose-dependent skin adverse effects.
Can local delivery of IL-22 in the gut promote epithelial barrier healing in IBD patients without systemic toxicity?
Rutz 2014, Chi 2014, Wang 2014 , Stefanich 2018, Sugimoto 2008, Rothenberg 2018
© 2021 SYNLOGIC. ALL RIGHTS RESERVED.
Synthetic Biotics: A Novel Approach to Immune Diseases
Exploiting the Interaction Between Bacteria and the Immune System
Bacteria and Immune System are Intimately
Linked
Immune system has evolved to recognize bacteria
Bacteria have evolved mechanisms to control the immune response
Synthetic Biotics Enable Unique Therapeutic
Opportunities
- Bacteria has evolved to survive the gastrointestinal tract
- Local delivery to the site of disease
Synthetic Biotics Enable Multiple Therapeutic
Modalities
- Ability to deploy multiple pathways
- Broad expression of bacterial and mammalian effectors
© 2021 SYNLOGIC. ALL RIGHTS RESERVED.
Attachments
Original document
Permalink
Disclaimer
Synlogic Inc. published this content on 21 May 2021 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 24 May 2021 07:48:07 UTC .
Synlogic, Inc. Announces Board Changes
Mar. 21
CI
North American Morning Briefing : Investors -2-
Mar. 21
DJ
HC Wainwright Upgrades Synlogic to Neutral From Sell
Mar. 20
MT
Earnings Flash (SYBX) SYNLOGIC Reports Q4 Revenue $2.8M
Mar. 19
MT
Synlogic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 19
CI
Synlogic, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 19
CI
Synlogic Board Approves Poison Pill Defense After Unsolicited Accumulation of Shares
Feb. 20
MT
Synlogic Engages Ladenburg Thalmann & Co. Inc. to Assist in Strategic Review
Feb. 19
CI
Cable Car Capital Discloses its Views on Synlogic
Feb. 16
CI
North American Morning Briefing : Stock Futures -2-
Feb. 12
DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Feb. 09
MT
Sector Update: Health Care
Feb. 09
MT
Synlogic Shares Fall After Move to Cease Operations, Cut Over 90% of Workforce
Feb. 09
MT
Wall Street Set to Open Modestly Higher as S&P Hovers Just Above 5,000
Feb. 09
MT
Chardan Downgrades Synlogic to Neutral From Buy on Early Termination of Synpheny-3 Trial
Feb. 09
MT
Leerink Partners Downgrades Synlogic to Market Perform From Outperform, Adjusts PT to $1 From $6
Feb. 09
MT
US Futures Nudge Higher as S&P Remains Just Above 5,000
Feb. 09
MT
HC Wainwright Downgrades Synlogic to Sell From Buy
Feb. 09
MT
Top Premarket Decliners
Feb. 09
MT
North American Morning Briefing : Stock Futures Rise; S&P 500 Again Tests 5,000 Milestone
Feb. 09
DJ
Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer
Feb. 08
CI
Synlogic, Inc. Announces Decision to Discontinue Synpheny-3 Study
Feb. 08
CI
Synlogic, Inc. Announces to Cease Operations
Feb. 08
CI
Synlogic, Inc. Announces Departure of Aoife Brennan as President
Feb. 08
CI
Synlogic to Evaluate Strategic Options
Feb. 07
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. It designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Companyâs preclinical work includes additional metabolic disease research.
More about the company
Last Close Price
1.68
USD
Average target price
1
USD
Spread / Average Target
-40.48%
Consensus
1st Jan change
Capi.
-56.36% 19.57M +33.37% 50.85B +1.55% 42.82B +49.11% 42.03B -4.22% 29.55B +11.57% 26.11B -21.00% 19.13B +7.36% 13.05B +28.30% 12.16B +23.80% 12.08B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1